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Lower serotonin transporter binding in
patients with cervical dystonia is associated
with psychiatric symptoms
E. Zoons1* , J. Booij2, J. D. Speelman1, Y. E. M. Dreissen1, M. Smit3 and M. A. J. Tijssen3
Abstract
Background: Cervical dystonia (CD) is often accompanied by depressive symptoms, anxiety, and jerks/tremor. The
dopamine transporter (DAT) binding is related with both depressive symptoms and jerks/tremor in CD. Serotonergic
and dopaminergic systems are closely related. As serotonin is involved in the pathophysiology of psychiatric symptoms
and jerks, we expected an altered serotoninergic system in CD. We hypothesized that CD is associated with reduced
serotonin transporter (SERT) binding, more specific that SERT binding is lower in CD patients with psychiatric
symptoms and/or jerks/tremor compared to those without, and to controls. The balance between SERT and DAT
binding can be altered in different CD phenotypes.
Results: In 23 CD patients and 14 healthy controls, SERT binding in the diencephalon/midbrain was assessed using
[123I]FP-CIT SPECT, with a brain-dedicated system. The specific to non-specific binding ratio (binding potential; BPND) to
SERT was the main outcome measure. There was a clear trend towards reduced SERT BPND in CD patients with
psychiatric symptoms compared to those without (p = 0.05). There was no correlation between SERT binding and
dystonia, jerks, or anxiety. There was a significant positive correlation between extrastriatal SERT and striatal DAT BPND
in CD patients with jerks, but not in patients without jerks.
Conclusion: CD patients with psychiatric symptoms have lower SERT binding in the midbrain/diencephalon, while
dystonia and jerks appear unrelated to SERT binding. The balance between extrastriatal SERT and striatal DAT binding
is different in CD with and without jerks.
Keywords: Cervical dystonia, SPECT, Serotonin transporter (SERT), Depression
Background
Dystonia is a syndrome characterized by sustained or
intermittent muscle contractions causing abnormal, often
repetitive, movements, postures, or both. Idiopathic
cervical dystonia (CD; dystonia of the neck) is the most
common form of dystonia [1]. Dystonia has commonly
been assumed to be a disorder of the dopaminergic system
[2]. Previous imaging studies in different types of dystonia
have mostly shown normal radiotracer binding to striatal
dopamine transporters (DAT) and normal or decreased
binding to striatal dopamine D2/3 receptors (D2/3 recep-
tors) [3, 4]. We recently showed normal striatal DAT
binding but decreased D2/3 receptor binding in CD. We
also showed a significant relationship between striatal
DAT binding and jerks/tremor of the head, which is a
common symptom in CD, and a significant and negative
relationship between both striatal DAT and D2/3 receptor
binding and depressive symptoms [5].
Psychiatric symptoms, mainly depressive symptoms
and anxiety, are very common in patients with dys-
tonia with an estimated lifetime prevalence between
40 and 70% [6] and are thought to be part of the
dystonia phenotype [6]. Single photon emission com-
puted tomography (SPECT) and positron emission
tomography (PET) imaging studies in patients with
major depression mostly showed reduced serotonin
transporter (SERT) binding [7, 8]. Reduced SERT
binding in depression is hypothesized to reflect de-
creased expression of SERTs. In line with this, post-
mortem studies in patients with major depressive
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disorder found reduced expression of SERTs in sev-
eral brain regions including the midbrain [9].
The role of serotonin in dystonia has not been studied
with imaging or postmortem, but there are strong indi-
cations that alterations of the serotonergic system may
indeed play a role. There have been many case reports
of drug-induced dystonia after the use of selective
serotonin reuptake inhibitors (SSRIs) [10]. Furthermore,
studies in patients with dopa-responsive dystonia and
idiopathic adult-onset dystonia found decreased levels of
serotonin metabolites, mainly 5-hydroxyindoleacetic acid
(5-HIAA), in cerebrospinal fluid [11, 12]. In the rare
genetic syndrome of 5-HIAA deficiency, serotonin levels
are low in the brain and patients suffer from dystonia
[13]. In addition, the role of serotonin in myoclonus
pathophysiology gained more attention lately [14], and
approximately 50% of CD patients have myoclonus
(jerks) or tremor of the head [15].
There are strong clues that the brain serotonin and
dopamine systems are closely interrelated. In a rat study,
long-term treatment with SSRIs led to a significant reduc-
tion of tyrosine hydroxylase, an important enzyme in the
biosynthesis of dopamine, in the substantia nigra and stri-
atum [16]. Furthermore, dopaminergic neurons contain
serotonin receptors, and serotonergic neurons contain
dopamine receptors [16]. In an animal model for myoclo-
nus dystonia, an inherited form of dystonia caused by a
mutation in the epsilon-sarcoglycan gene (SCGE); the hy-
pothesis of a dysbalanced dopamine-serotonin system has
been confirmed. SCGE knockout mice show all the signs
of dystonia, from jerks to depression-like behavior. After
sacrificing, neurochemical studies in the striata of these
mice showed increased levels of dopamine metabolites
that correlated with motor performance (dystonia and
jerks), while the level of serotonin metabolites, that was
not significantly different from wild-type mice, inversely
correlated with motor performance [17]. Jerks in CD, that
resemble myoclonus in myoclonus dystonia, may also be
related to alterations of the serotonin system.
Our hypothesis was that CD is associated with reduced
SERT binding, especially in CD patients with psychiatric
symptoms. Because of the relation of both dopamine and
serotonin metabolites and motor performance, including
jerks, in SCGE knockout mice, we expected the balance be-
tween DAT and SERT binding to be different in CD
patients with jerks compared to those without. We tested
these hypotheses by imaging SERT in the diencephalon/




Included subjects also participated in another study re-
cently published [5]. In short, we included patients with
idiopathic CD with stable disease severity for at least
1 year on the Tsui scale, age between 35 and 80 years,
and ongoing treatment with botulinum neurotoxin
(BoNT) injections, which is the current standard treat-
ment for focal dystonia. BoNT injections were adminis-
tered on the day of SPECT scanning or a maximum of
7 days prior to or after scanning. Exclusion criteria were
other relevant neurological conditions at inclusion or in
the past, treatment with deep brain stimulation (DBS),
use of medication with a known dopaminergic or seroto-
nergic effect in the past 6 months, including SSRIs [18],
and pregnancy or lactation. Patients were allowed to use
other medication including low-dose benzodiazepines
(for example clonazepam 1 mg twice daily). Healthy age-
and sex-matched subjects with a normal neurological
examination and no self-reported (family) history of
dystonia, myoclonus, or psychiatric illness recruited
through flyers and databases served as the control
group. Written informed consent was obtained in all
subjects, and the study was approved by the local
medical ethics committee.
Scoring neurological and psychiatric symptoms
The neurological examination of patients was videotaped
and blindly scored by two independent clinicians. The
Toronto Western Spasmodic Torticollis Rating Scale
(TWSTRS) [19] and the Tsui scale were used to score dys-
tonic symptoms [20]. The Unified Myoclonic Rating Scale
(UMRS) was used to score jerks [21]. In our previous
study [5], we showed good interobserver agreement for
the TWSRTS and Tsui (> 0.80 intraclass correlation coeffi-
cients) and reasonable agreement for the UMRS (0.73
intraclass correlation coefficients). The average score of
the two experts on the Tsui, TWSTRS, and UMRS was
used in the statistical analysis. The psychiatric examination
consisted of an interview, performed by a trained investi-
gator (EZ; YD). The Mini International Neuropsychiatric
Interview (MINI)-Plus and Montgomery-Åsberg Depres-
sion Rating Scale (MADRS) were included, as well as sev-
eral questionnaires concerning symptoms of depression
(Beck Depression Inventory (BDI)) and anxiety (Liebowitz
Social Anxiety Scale (LSAS) and the Beck Anxiety
Inventory (BAI)for anxiety ). The psychiatric interview
was performed on the day of the SPECT scan, and ques-
tionnaires were answered in the week preceding the
SPECT scan. Subjects were judged to have a depressive
disorder when they fulfilled the according criteria on the
MINI (current depression) and/or had a BDI ≥ 14 points
or MADRS ≥ 20 points, consistent with moderate-severe
depression. Subjects were judged to have an anxiety dis-
order when they fulfilled the according criteria on the
MINI (current anxiety disorder) and/or had a BAI ≥ 16
points or LSAS ≥ 30 points, consistent with moderate-
severe anxiety.
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SPECT imaging
All subjects received 300 mg potassium iodide (three
capsules of 100 mg each) to block thyroid uptake of free
radioactive iodide before administration of the tracer.
Then, all subjects received a mean dose of 100 MBq
(2.7 mCi) [123I]FP-CIT intravenously (produced accord-
ing to GMP criteria by GE Healthcare) as a single bolus
[22]. Scans were acquired 2 h after bolus injection to
optimally visualize extrastriatal SERT binding, a tech-
nique that has been validated before [23]. SPECT studies
were performed using a 12-detector single-slice brain-
dedicated scanner (Neurofocus 810, which is an upgrade
of the Strichman Medical Equipment); this system was
described extensively by Stoddart and Stoddart [24], with
a full-width at half-maximum in-slice resolution of ap-
proximately 5–6 mm, throughout the 20-cm field-of-
view, and a system volume sensitivity of 0.22 (counts/s)/
(Bq/ml) [25]. After positioning of the subjects with the
head parallel to the orbitomeatal line, axial slices paral-
lel, and upward from the orbitomeatal line to the vertex
were acquired in 5-mm steps. An average of 15 slices
with 3.5-min scanning time per slice was acquired in a
64 × 64 matrix. The energy window was set at 140–
178 keV. Images were corrected for attenuation, as earl-
ier described, and reconstructed in a 3-D mode using
Neurofocus proprietary software (Neurofocus Inc., USA)
and the manufacturer’s recommended iterative recon-
struction algorithm, which was based on maximum a-
posteriori (MAP) reconstruction methods [26]. The 3-D
reconstructed images were randomly numbered and an-
alyzed blinded for the subject group (CD patient with/
without jerks or control) by one observer (EZ). Fixed
regions of interest (ROIs) for the diencephalon and
midbrain combined were positioned as earlier de-
scribed [23, 27]. The four consecutive slices with
highest activity in the ROI were pooled together, and
average activity was calculated. This was also done
for the cerebellum as reference region using the two
to three consecutive slices with highest activity. Spe-
cific to non-specific binding ratio was calculated as
[(activity in ROI − activity in reference region)/activ-
ity in reference region], representing the binding po-
tential (BPND) [28]. Test-retest variability of this
analysis was calculated in a random subset of subjects
(n = 10) by using the formula (test-retest)/((test + re-
test)/2) × 100%. Average variability was 10%, which is
comparable to previously published variability in
extrastriatal [123I]FP-CIT binding in the midbrain [29]
and only slightly higher than variability in striatal
[123I]FP-CIT binding, which is ~ 7.5% [22].
As published before [5], we also measured DAT BPND
in the striatum 3 h after the same [123I]FP-CIT injection
in the same subjects. We used these values to test the
correlation between SERT and DAT BPND.
Statistical analysis
Mann-Whitney U test and Kruskal-Wallis test were
used to assess differences in baseline characteristics,
SERT BPND, and SERT to DAT ratio between differ-
ent groups of subjects. Chi-square and Fisher’s exact
test were used to assess dichotomous variables. Linear
regression was used to assess if differences in baseline
characteristics explained differences in SERT BPND,
both between patients with and without jerks/tremor,
and between CD patients and healthy controls. Linear
regression was also used for assessing relationships
between SERT BPND and motor and psychiatric
scores. Since age and sex are known to have an effect
on SERT BPND as measured with [
123I]FP-CIT SPECT
[30], we corrected for these factors. Analyses were
carried out using SPSS version 23, and differences
were considered significant at p < 0.05.
Results
Clinical characteristics
We planned to include 29 CD patients and compare
them to 15 matched healthy controls. Due to technical
difficulties, one [123I]FP-CIT scan of a control and six
[123I]FP-CIT scans of patients had to be removed from
the analysis. More specific, not in all scans the whole
cerebellum was scanned because of a skewed position of
the head (the brain-dedicated system is a tomographic
system), and consequently, this region could not be used
as a reliable reference region [5]. We could use data
from 23 CD patients (12 with jerks/tremor and 11 with-
out) and 14 controls. Baseline characteristics are
depicted in Table 1, no significant differences between
groups were detected. Low-dose benzodiazepines were
used by 6/23 patients: oxazepam or diazepam on as
needed base (three patients), oxazepam 5 mg once daily
(one patient), and clonazepam 0.5 mg once or twice
daily (two patients). In total, 8/11 (73%) of the patients
without comorbid jerks/tremor fulfilled the criteria for a
psychiatric diagnosis (any diagnosis on the MINI and/or
a score above the before mentioned cutoff values on the
BDI, MADRS, LSAS, or BAI) compared to 6/12 (50%) of
the patients with comorbid jerks/tremor. The most com-
mon condition was social anxiety disorder (7/23
patients; 30%). In one patient, both a depressive disorder
as well as social anxiety disorder were present. As men-
tioned in our previous study, one control fulfilled the
criteria for alcohol abuse in the past and one control
scored 34 on the LSAS meeting the criteria of social
anxiety disorder [5].
[123I]FP-CIT SPECT—serotonin transporter
Median SERT BPND was 0.26 in controls (IQR 0.10–
0.40) and 0.25 in patients (IQR 0.13–0.40; p = 0.89,
Mann-Whitney U test). In addition, median SERT
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BPND was not significantly different in patients with
jerks/tremor (0.28; IQR 0.15–0.42) compared to
patients without jerks/tremor (0.17; IQR 0.11–0.34;
p = 0.49, Mann-Whitney U test). There was no sig-
nificant correlation between the diencephalon/mid-
brain SERT BPND and scores on Tsui (p = 0.79),
TWSTRS (p = 0.20), or UMRS (p = 0.32; linear re-
gression) in CD patients.
Median SERT BPND was 0.20 in patients with psychi-
atric co-morbidity (n = 14; IQR 0.11–0.28) and 0.42 in
patients without a psychiatric diagnosis (n = 9; IQR
0.16–0.47; p = 0.05, Mann-Whitney U test). This trend
was not present between patients with any anxiety dis-
order (n = 10; median SERT BPND 0.24 (IQR 0.15–0.28))
and patients without any anxiety disorder (n = 13;
median SERT BPND 0.31 (IQR 0.11–0.44); p = 0.45,
Mann-Whitney U test). There was a trend towards a dif-
ference between patients with a depression (n = 5;
median SERT BPND 0.14 (IQR 0.10–0.22)) and patients
without (n = 18; median SERT BPND 0.28 (IQR 0.15–
0.42); p = 0.09, Mann-Whitney U test). There was no
significant correlation between the diencephalon/mid-
brain SERT BPND and scores on BDI (p = 0.43), MADRS
(p = 0.43), LSAS (p = 0.29), or BAI (p = 0.34, linear re-
gression) in CD patients.
Correcting for age and sex by means of linear re-
gression did not change the results in any of our ana-
lyses. Regression coefficients and p values before and
after correction are depicted in Table 2.
DAT and SERT BPND
There was a statistically significant correlation between
the diencephalon/midbrain SERT BPND and striatal DAT
BPND in patients with jerks (R
2 0.51, regression coeffi-
cient 0.27 (0.06–0.49; p = 0.02; see Fig. 1b). Correcting
for any psychiatric diagnosis or depression did not
change these results significantly. This correlation was
not present in patients without jerks (R2 0.04, regression
coefficient − 0.11–0.20; p = 0.56, see Fig. 1a) or in con-
trols (p = 0.14, see Fig. 1c).
Discussion
This study did not show significant differences in the
diencephalon/midbrain SERT binding in patients with
idiopathic CD compared to controls. However, we did
find a trend (p = 0.05) towards decreased diencephalon/
midbrain SERT BPND in CD patients with psychiatric
comorbidity and in CD patients with a depression com-
pared to those without. In this group, results failed to
reach significance, likely due to the small number of CD
patients with depression (n = 5). Furthermore, a signifi-
cant correlation between the diencephalon/midbrain
SERT and striatal DAT binding in CD patients with jerks
was detected. This correlation was not present in
controls and CD patients without jerks.
A trend towards reduced diencephalon/midbrain
SERT BPND in CD patients with depression is consistent
with results previously reported in patients with major
depressive disorder, but without dystonia [9]. Reduced
SERT binding can be caused by reduced expression of
SERTs on serotonergic neurons and/or increased occu-
pancy of the SERT by high levels of endogenous synaptic
serotonin. Considering that postmortem studies in major
depression found reduced numbers of SERTs in the mid-
brain, the first theory seems more likely. Furthermore,
PET studies in depression have also showed increased
Table 1 Baseline characteristics
Characteristics CD with jerks (n = 12) CD without jerks (n = 11) Controls (n = 14) p value
Age, y, median (IQR) 62 (51.5–63.75) 54 (46–62) 61 (55–62) 0.27
Men, n (%) 6 (50%) 5 (45%) 7 (50%) 0.97
Tsui, median (IQR) 9 (7.5–13) 7.5 (5–14) N/A 0.49
TWSTRS total, median (IQR) 16.5 (14.5–21) 14 (13.5–19) N/A 0.28
UMRS, median (range) 12.5 (7–19) 1 (0.5–2) N/A < 0.001
Psychiatric disorders, n (%) 6 (50%) 8 (73%) 2 (14%) 0.01
Anxiety disorder, n (%) 4 (33%) 6 (55%) 1 (7%) 0.03
Depressive disorder, n (%) 2 (17%) 3 (27%) 0 (0%) 0.13
BDI, median (IQR) 4.5 (2.25–9.5) 5 (3–9) 1.5 (0–3) 0.007
MADRS, median (IQR) 2 (0–3.75) 4 (0–9) 0.5 (0–2) 0.03
LSAS, median (IQR) 10.5 (2–33.5) 17 (5–44) 4 (0.75–8.5) 0.03
BAI, median (IQR) 5.5 (3.25–12.25) 4 (1–12) 0.5 (0–1) 0.002
p values are depicted for comparisons between the three groups in all cases except for Tsui, TWSTRS, and UMRS, where only the two groups of patients are compared
BAI Beck Anxiety Inventory, BDI Beck Depression Inventory, CD cervical dystonia, IQR interquartile range, LSAS Leibowitz Social Anxiety Scale, MADRS Montgomery-
Åsberg Depression Rating Scale, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale, UMRS Unified Myoclonic Rating Scale
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binding to serotonin 1A receptors, both the postsynaptic
receptors on target neurons throughout the brain as well
as the presynaptic autoreceptors in the raphe nuclei.
This is in both cases hypothesized to reflect increased
number of receptors. The higher number of autorecep-
tors in the raphe nuclei results in a lower firing
frequency and thus reduced synaptic release of serotonin
[31]. If this is also the case in patients with CD, this
would explain the reduced level of serotonin metabolites
that was found in cerebrospinal fluid of dystonia pa-
tients, and supports also our postulate that the currently
observed lower SERT binding is not caused by an in-
creased release of serotonin [11]. It would be interesting
to confirm this theory in a future study in CD with a
selective serotonin 1A receptor PET tracer such as
[11C]WAY-100635.
We found a statistically significant and positive correl-
ation between striatal DAT and extrastriatal SERT BPND
in CD patients with jerks, that was not present in pa-
tients without jerks. This might indicate that the
relationship between SERT and DAT binding influences
the motor phenotype of CD, more specifically whether a
patient develops jerks or not. Recent studies in Parkin-
son’s disease (PD) have shown that the relative amount
of DATs and SERTs can be imbalanced and lead to
complications. After 5–10 years, patients with PD often
develop levodopa-induced dyskinesias (LIDs), and these
LIDs are associated with relatively intact serotonergic
nerve terminals. PD patients with more available sero-
tonin nerve terminals are more likely to develop LIDs
[32]. In agreement with this hypothesis, the striatal
SERT/DAT ratio was higher in PD patients suffering
Table 2 Regression analyses for extrastriatal SERT binding corrected for age and sex
Regression coefficient
before correction
p value before correction Regression coefficient
corrected for age and sex
p value corrected for
age and sex
Patients vs controls (95% CI) −0.04 (−0.17-0.10) 0.59 −0.03 (−0.18-0.11) 0.62
Jerks vs no jerks (95% CI) 0.04 (−0.10-0.18) 0.55 0.04 (−0.12-0.19) 0.62
Psychiatry vs no psychiatry (95% CI) −0.13 (−0.26-(−0.01)) 0.04 −0.14 (−0.28–(−0.00)) 0.05
Anxiety vs no anxiety (95% CI) −0.08 (−0.21-0.06) 0.24 −0.08 (−0.23-0.07) 0.27
Depression vs no depression (95% CI) −0.12 (−0.28-0.04) 0.14 −0.14 (−0.31-0.03) 0.10
Fig. 1 The correlation between striatal DAT BPND and the diencephalon/midbrain SERT BPND is shown for the three groups separately. a CD
patients without jerks, b CD patients with jerks, c Controls
Zoons et al. EJNMMI Research  (2017) 7:87 Page 5 of 7
from LID than without [33]. In our patients with jerks,
higher SERT BPND was related to higher DAT BPND
which might indicate that CD patients with jerks also
have more intact serotonergic nerve terminals. This
hypothesis should be tested in future studies, as has
been suggested for the development of LIDs in PD [33].
This study has several limitations [5]. We did not ob-
tain data on disease duration. These data are difficult to
obtain, as CD often starts with mild complaints and it
can take months to years before the right diagnosis is
made. Furthermore, psychiatric symptoms, which are
now considered part of the phenotype, often precede
motor symptoms, making it difficult to establish exactly
the moment the disease started [6]. Patients in our study
were not allowed to use any dopaminergic or serotoner-
gic medication that may influence [123I]FP-CIT binding
in vivo [18]; however, they received BoNT injections and
were allowed to use benzodiazepines. Furthermore, most
subjects used medication for other conditions. Patients
were scanned within a week of BoNT administration,
making it unlikely that BoNT had an effect on SERT
binding ratios. Also, no significant effect of benzodiaze-
pines on [123I]FP-CIT binding has been described.
Patients in our study used a low dosage of oxazepam or
clonazepam. We do not think this has influenced our re-
sults. [123I]FP-CIT is metabolized by cytochrome P450
type 3A (CYP3A) in the liver, which metabolizes most
drugs. Therefore, many drugs might influence [123I]FP-
CIT metabolism and possibly SERT binding (see discus-
sion in Booij and Kemp [18]). The only potential
influence we found was codeine, which was used by one
of our patients in a low dose, making it unlikely this in-
fluenced our results. Furthermore, this subject had a
SERT BPND of 0.23 which is around the group median.
The radiotracer we used is not a selective radiotracer
for SERT. [123I]FP-CIT binds both to striatal DAT and
extrastriatal SERT, while, for example, [123I]ADAM is
highly SERT-selective. We chose to use [123I]FP-CIT in
this study so we could image both striatal DAT and
extrastriatal SERT in one scanning session, limiting the
number of visits and the exposure to radiation for our
participants. Imaging the SERT in extrastriatal brain
areas with [123I]FP-CIT SPECT is well validated and
done before by several groups in several different patient
populations [30, 34]. Moreover, in this study, extrastria-
tal SERT has been examined 2 h after bolus injection,
which has been validated previously, and offers the ad-
vantage of relatively high count statistics [23]. One fac-
tor to take into account is the small, but not negligible,
number of serotonergic neurons, and consequently
SERT, in the cerebellum, which was used as a reference
region, and consequently, we feel it is unlikely that using
the cerebellar binding to assess non-specific binding has
significantly influenced our results.
SERTs are highly present in the diencephalon/mid-
brain but are also present in striatum. SERTs in the stri-
atum are highly outnumbered by DATs making it
impossible to measure SERT in the striatum with
[123I]FP-CIT. In future studies, it may be of interest to
use selective SERT tracers to evaluate whether our
present observations on the diencephalon/midbrain
SERT binding are also true for striatal SERT binding.
Another limitation of this study is the significant num-
ber of scans that had to be excluded from the analysis.
Taking this in regard, we still have the largest SPECT
imaging study in patients with dystonia thus far, as well
as the first study to investigate SERT binding in CD.
Conclusions
In conclusion, we are the first to show that psychiatric
symptoms in CD patients are associated with a trend to-
wards lower extrastriatal SERT binding, while dystonia
itself is not related to lower extrastriatal SERT binding.
Patients with a relatively intact serotonin system and
with a significant correlation between SERT and DAT
binding might be more likely to develop jerks, a hypoth-
esis to be tested in future longitudinal studies.
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